Sellheyer Klaus, Cribier Bernard, Nelson Paula, Kutzner Heinz, Rütten Arno
Department of Dermatology, Cleveland Clinic Foundation, Cleveland, OH, USA.
J Cutan Pathol. 2013 May;40(5):455-62. doi: 10.1111/cup.12107. Epub 2013 Mar 14.
Until the 1990s, basal cell carcinoma (BCC) was viewed as the most common epithelial neoplasm developing in association with nevus sebaceus (NS). Currently, trichoblastoma is thought of as the most prevalent basaloid neoplasm in NS. The follicular stem cell marker pleckstrin homology-like domain, family A, member 1 (PHLDA1) also known as T-cell death-associated gene 51 (TDAG51) labels trichoepithelioma (TE) but not BCC. Therefore, we explored its usefulness in basaloid neoplasms developing in NS.
We studied immunohistochemically PHLDA1 in 10 nodular BCCs, 11 TEs, 11 trichoblastomas and 25 NS with basaloid tumors. Additionally, we examined the expression of BCC marker BerEP4 and the distribution of Merkel cells that function as surrogate markers for benign follicular neoplasms.
Nineteen of the 25 basaloid tumors in NS were PHLDA1-negative comparable to BCC arising de novo and six tumors were PHLDA1-positive comparable to solitary trichoblastomas and TEs. Fewer Merkel cells were seen in BCCs associated with NS when compared with trichoblastoma. BerEP4 did not discriminate between the neoplasms.
We raise concern that the unquestioned assessment that basaloid tumors developing in association with NS represent mostly trichoblastomas and not BCC may not be true. This influences clinical care, as it is paramount in the decision of whether to excise these lesions or not.
直到20世纪90年代,基底细胞癌(BCC)一直被视为与皮脂腺痣(NS)相关的最常见上皮性肿瘤。目前,毛母细胞瘤被认为是NS中最常见的基底样肿瘤。毛囊干细胞标志物pleckstrin同源样结构域A家族成员1(PHLDA1),也称为T细胞死亡相关基因51(TDAG51),可标记毛发上皮瘤(TE),但不能标记BCC。因此,我们探讨了其在NS中发生的基底样肿瘤中的应用价值。
我们采用免疫组织化学方法研究了10例结节性BCC、11例TE、11例毛母细胞瘤和25例伴有基底样肿瘤的NS中PHLDA1的表达情况。此外,我们还检测了BCC标志物BerEP4的表达以及作为良性毛囊肿瘤替代标志物的默克尔细胞的分布。
25例NS中的基底样肿瘤中有19例PHLDA1阴性,与新发BCC相似,6例肿瘤PHLDA1阳性,与孤立性毛母细胞瘤和TE相似。与毛母细胞瘤相比,NS相关BCC中可见的默克尔细胞较少。BerEP4无法区分这些肿瘤。
我们担心,与NS相关的基底样肿瘤大多为毛母细胞瘤而非BCC这一未经质疑的评估可能并不正确。这会影响临床治疗,因为这在决定是否切除这些病变时至关重要。